GNA11 and neoplasm: Carita et al. demonstrated therapeutic efficacy for combination of PKC/mTOR inhibitors with PKC/p53-MDM2 inhibitors or mTORC1 inhibitors, both of which resulted in tumour regression in PDX mouse models by targeting the PKC pathway downstream of GNAQ and GNA11 driver mutations 56.